Edgewise Therapeutics (EWTX)
(Delayed Data from NSDQ)
$17.41 USD
+0.28 (1.63%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $17.40 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$17.41 USD
+0.28 (1.63%)
Updated Jun 3, 2024 04:00 PM ET
After-Market: $17.40 -0.01 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth B Momentum D VGM
Zacks News
Wall Street Analysts Predict a 52.78% Upside in Edgewise Therapeutics, Inc. (EWTX): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 52.8% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts See a 33.27% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 33.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 70.76%: Read This Before Placing a Bet
by Zacks Equity Research
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 70.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Edgewise (EWTX) Rallies 35% on Issue of New Common Stock
by Zacks Equity Research
Edgewise (EWTX) will issue secondary shares to raise $240 million in gross proceeds. The capital will be used to fund key initiatives, including the potential commercial launch of lead pipeline drugs.
Wall Street Analysts See a 310.1% Upside in Edgewise Therapeutics, Inc. (EWTX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 310.1% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Wall Street Analysts Think Edgewise Therapeutics, Inc. (EWTX) Could Surge 327.91%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 327.9% in Edgewise Therapeutics, Inc. (EWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 224.25%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 224.3% in Edgewise Therapeutics, Inc. (EWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 133%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Edgewise Therapeutics, Inc. (EWTX) points to a 133.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Edgewise Therapeutics, Inc. (EWTX) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Edgewise Therapeutics, Inc. (EWTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Wall Street Analysts Believe Edgewise Therapeutics, Inc. (EWTX) Could Rally 157%: Here's is How to Trade
by Zacks Equity Research
The consensus price target hints at a 156.9% upside potential for Edgewise Therapeutics, Inc. (EWTX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Edgewise (EWTX) Up 9.37% on Positive Data From BMD Study
by Zacks Equity Research
Edgewise (EWTX) stock gains on upbeat interim results from the ARCH study of its lead candidate EDG-5506 in adults with Becker Muscular Dystrophy (BMD).